RSVpreF (bivalent RSV prefusion F protein vaccine)

The vaccine substance in Abrysvo: stabilised RSV prefusion F proteins of the A and B types in one vaccine. It is the substance tested in the MATISSE trial.

Also called RSVpreF

Drug
In this atlas

Overview

Technical summary

A fixed combination of the RSV A and B stabilised prefusion F protein drug substances (US approval letter; MATISSE abstract: a bivalent RSV prefusion F protein-based vaccine). RxNorm precise-ingredient concepts for the A and B proteins are RXCUI 2642138 and 2642139, recorded as broad codes because each is one part of the combination; they were looked up in RxNav, not quoted. The product is Abrysvo.

About this drug

Level: Combination
Mechanism: Bivalent vaccine based on stabilised RSV prefusion F proteins A and B (US approval letter and trial abstract); the sources read do not describe how it works.

Classification codes

RxNorm 2642138
RxNorm 2642139

Claims and evidence

No claims are published for this drug yet.

Record details

Record id: maternal:rsvpref-vaccine
Content hash: 08ba54c44a90604df24d75368320f29d4d7079eb6a197d25a4df200d2a61b14b